𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ Scribed by J de Castro Carpeño; A Castro Gómez; S Walzer


Book ID
118611933
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
94 KB
Volume
12
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES